Brief: Ascentage Pharma Group International Says Its APG-115 Granted Approval For Phase Ib/Ii Clinical Study In China
27/10/2020 01:49
Oct 27 (Reuters) - Ascentage Pharma Group International
6855.HK :
* CO'S APG-115 GRANTED APPROVAL FOR PHASE IB/II CLINICAL
STUDY IN
CHINA
Source text for Eikon: urn:newsml:reuters.com:*:nHKS75zWJX
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up